Pipeline Overview

Program
Target
Indications
Discovery
Pre-clinical development
Early development
Late development
Rights
Program: Cemsidomide
Target: IKZF1/3
Multiple Myeloma & Non-Hodgkin's Lymphoma
Indications Multiple Myeloma & Non-Hodgkin's Lymphoma
MM in 4L+: Phase 2 trial in combination with dexamethasone, expected Q1 2026
Early development
Indications Multiple Myeloma & Non-Hodgkin's Lymphoma
MM in 2L+: Phase 1b trial in combination with dexamethasone and elranatamab, expected Q2 2026
Early development
Indications Multiple Myeloma & Non-Hodgkin's Lymphoma
NHL
Early development
Right 1
Program: CFT8919¹
Target: EGFR L858R
Non-Small Cell Lung Cancer
Indications Non-Small Cell Lung Cancer
Early development
Right 1 Right 2
Program: CFT1946²
Target: BRAF V600 Mutant
V600 Mutant Cancers
Indications V600 Mutant Cancers
CRC, Melanoma, Other
Early development
Right 1
Program: Discovery Stage Programs³
Oncology & Non-Oncology Indications
Indications Oncology & Non-Oncology Indications
Discovery
Right 1

1 License and collaboration agreement with Betta Pharmaceuticals for development and commercialization in Greater China

2 In May 2025, C4T announced CFT1946 will not advance beyond Phase 1 and that the company will seek partnership for the BRAF program

3 C4T is pursuing 5 targets in the following pathways: IL-23/IL-17; Type 1 IFN; MAPK, P13K/AKT, NF-kB

Learn more about our partnerships